Present and Future of Personalised Medicine for Endocrine Cancers

Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients...

Full description

Saved in:

Bibliographic Details
Format:	Online
Language:	English
Published:	MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:	papillary thyroid cancer SUV PET/CT BRAF V600E immune checkpoint inhibitors (ICIs) ipilimumab nivolumab prolactinoma Cushing’s disease aggressive pituitary tumor aggressive PitNET aggressive pituitary adenoma pituitary carcinoma adrenocortical cancer adrenal adenomas adrenal tumors p53 p27 ki-67 reticulin mitotane adjuvant treatment recurrence recurrence free survival timing intratumoral heterogeneity thyroid tumor BRAF RET/PTC rearrangements RAS mutation adrenal cortex carcinoma angiogenesis gene expression osteopontin hyaluronan synthase 1 multikinase inhibitors sorafenib lenvatinib differentiated thyroid cancer radioiodine resistance predictive marker predictors response to treatment survival information needs and preferences focus group interview personalized medicine neuroendocrine tumours phaeochromocytoma paraganglioma molecular clusters n/a thema EDItEUR::M Medicine and Nursing
Online Access:	ONIX_20220621_9783036543307_91
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Present and Future of Personalised Medicine for Endocrine Cancers

Similar Items